- Home
- GILD vs BX Comparison
GILD vs BX Comparison
Compare GILD & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BX
- Stock Information
- Founded
- GILD 1987
- BX 1985
- Country
- GILD United States
- BX United States
- Employees
- GILD N/A
- BX N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BX Investment Managers
- Sector
- GILD Health Care
- BX Finance
- Exchange
- GILD Nasdaq
- BX Nasdaq
- Market Cap
- GILD 140.8B
- BX 132.8B
- IPO Year
- GILD 1992
- BX 2007
- Fundamental
- Price
- GILD $119.02
- BX $174.41
- Analyst Decision
- GILD Buy
- BX Buy
- Analyst Count
- GILD 24
- BX 18
- Target Price
- GILD $114.26
- BX $166.00
- AVG Volume (30 Days)
- GILD 6.4M
- BX 3.6M
- Earning Date
- GILD 08-07-2025
- BX 07-24-2025
- Dividend Yield
- GILD 2.65%
- BX 2.26%
- EPS Growth
- GILD 496.80
- BX 41.09
- EPS
- GILD 5.01
- BX 3.70
- Revenue
- GILD $28,863,000,000.00
- BX $13,505,742,000.00
- Revenue This Year
- GILD $1.91
- BX $1.07
- Revenue Next Year
- GILD $3.75
- BX $27.37
- P/E Ratio
- GILD $23.75
- BX $47.23
- Revenue Growth
- GILD 3.81
- BX 37.02
- 52 Week Low
- GILD $72.89
- BX $115.66
- 52 Week High
- GILD $121.83
- BX $200.96
- Technical
- Relative Strength Index (RSI)
- GILD 60.91
- BX 61.00
- Support Level
- GILD $108.54
- BX $166.35
- Resistance Level
- GILD $121.83
- BX $177.41
- Average True Range (ATR)
- GILD 2.53
- BX 3.71
- MACD
- GILD 0.67
- BX -0.67
- Stochastic Oscillator
- GILD 78.86
- BX 63.57
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).